Please login to the form below

Not currently logged in

Incyte says Jakafi patient developed brain virus

Investigation to determine if myelofibrosis drug is linked to PML

Incyte Novartis Jakafi brain virus

Incyte and Novartis have been hit by the news that a patient on their myelofibrosis treatment Jakafi/Jakavi has developed progressive multifocal leukoencephalopathy (PML), the same side effect that led Biogen Idec's Tysabri to be suspended from sale in 2005.

A 75-year-old man treated with Jakafi (ruxolitinib) has developed the life-threatening condition - in which the myelin sheath that covers nerves in the brain is destroyed - and an independent investigation is now trying to determine whether the PML case is linked to the drug.

Incyte's share price fell yesterday as investors tried to gauge the seriousness of the announcement, which comes as a further blow after the UK's National Institute for Health and Clinical Excellence (NICE) said Jakavi should not be used within the National Health Service on cost-effectiveness grounds.

Ruxolitinib is sold as Jakafi by Incyte in the US and as Jakavi by Novartis elsewhere, and is indicated for patients with intermediate or high-risk myelofibrosis, a rare bone-marrow disease for which there is currently no therapy other than bone marrow or stem cell transplant.

"This is the only known case of PML in the approximately 9,800 myelofibrosis patients treated with ruxolitinib worldwide in clinical trials or with commercial product," said Incyte in a statement.

"There are reports in the medical literature that suggest that patients with myeloproliferative neoplasms, including myelofibrosis, may be at higher risk of developing PML," it added.

The drug was approved in the US in November 2011 and in Europe last August and while sales in myelofibrosis have been modest - around $136m in the US in 2012 - potential follow-on indications such as polycythemia vera, essential thrombocythemia and solid tumours could elevate it to blockbuster status, according to analysts.

A link to PML could put a brake on widespread use of Jakafi, although one thing in Incyte and Novartis' favour is the availability of a diagnostic for the JC virus, an infection which predisposes patients to develop PML. The test from Quest Diagnostics allows doctors to screen for patients who may be at risk of PML and exclude them from therapy.

Tysabri's tendency to cause the side effect has not stopped the multiple sclerosis (MS) treatment earning significant revenues since it was reintroduced in 2006.

Sales were $1.1bn last year and additional upside is expected now that the Quest kit can be used to screen patients, potentially allowing earlier use of the drug in MS patients.

19th March 2013

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...